Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current developments in anti-platelet therapy.

Florian B Mayr1, Bernd Jilma

  • 1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Wiener Medizinische Wochenschrift (1946)
|October 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant human diamine oxidase prevents histamine-induced hypoxia, shock and death in guinea pigs.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
Same author

Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: an updated meta-analysis.

Scientific reports·2026
Same author

Effects of an early restrictive versus liberal fluid strategy on long-term patient-centered outcomes in sepsis-induced hypotension: an open-label, randomized controlled trial.

American journal of respiratory and critical care medicine·2026
Same author

Abnormal whole-blood viscoelastic test results in patients with bleeding disorder of unknown cause.

Blood vessels, thrombosis & hemostasis·2026
Same author

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

American journal of hematology·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Anti-platelet drugs are crucial for preventing blood clots in cardiovascular diseases. This review covers four main classes of anti-platelet agents, including acetyl-salicylic acid (ASA), to manage thrombosis and related conditions.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Platelets are vital for hemostasis and blood clotting at vascular injury sites.
  • Pathologically, platelets are involved in thrombosis, a major cause of cardiovascular diseases.
  • Anti-platelet therapy is a cornerstone in treating and preventing conditions like myocardial infarction and stroke.

Purpose of the Study:

  • To provide a concise review of currently available anti-platelet agents.
  • To use acetyl-salicylic acid (ASA) as a reference standard for comparison.
  • To discuss four main classes of anti-platelet drugs used in clinical practice.

Main Methods:

  • Review of existing literature on anti-platelet agents.
  • Categorization of drugs into four main classes: acetyl-salicylic acid (ASA), phosphodiesterase (PDE) inhibitors, thienopyridines, and GPIIb/IIIa antagonists.

Related Experiment Videos

  • Comparative analysis using ASA as the benchmark.

    • Main Results:

    • Acetyl-salicylic acid (ASA) remains the most widely used anti-platelet drug.
    • Several other anti-platelet agents have been developed to target pathways not affected by ASA.
    • Four primary classes of anti-platelet agents are clinically available.

    Conclusions:

    • Anti-platelet therapy is essential for managing cardiovascular diseases.
    • Different classes of anti-platelet agents offer varied mechanisms to inhibit platelet function.
    • Understanding these classes is crucial for effective clinical application in thrombosis management.